Articles

A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy

Department of Leukemia, MD Anderson Cancer Center, Houston, USA
Hopital Saint Louis, Paris, France
Department of Internal Medicine II, Hubertus Wald Tumor Center, University Cancer Center, Hamburg, Germany
Department of Internal Medicine II, Hubertus Wald Tumor Center, University Cancer Center, Hamburg, Germany;Department of Hematology and Oncology, University Hospital of the RWTH Aachen, Germany
Hopital Saint Louis, Paris, France
Department of Leukemia, MD Anderson Cancer Center, Houston, USA
Clinical Organization for Strategies and Solutions S.r.l.(CLIOSS), Nerviano Medical Sciences, Italy
Clinical Organization for Strategies and Solutions S.r.l.(CLIOSS), Nerviano Medical Sciences, Italy
Oncology, Nerviano Medical Sciences, Italy
Clinical Organization for Strategies and Solutions S.r.l.(CLIOSS), Nerviano Medical Sciences, Italy
Department of Leukemia, MD Anderson Cancer Center, Houston, USA
Department of Leukemia, MD Anderson Cancer Center, Houston, USA
Vol. 100 No. 7 (2015): July, 2015 https://doi.org/10.3324/haematol.2014.115279